## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.5% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($175.93)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Quest Diagnostics Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170500 | Neutral | Relevance: 99%
-  Quest Diagnostics Inc. (DGX) stock fell 2.86% to $183.77 on Monday, experiencing its third consecutive day of losses. This underperformance occurred during a generally negative trading session, with the S&P 500 Index (SPX) down 0.53% and the Dow Jones Industrial Average (DJIA) down 0.90%.

**2. Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States**
- Source: Yahoo Finance | 20251201T200828 | Bullish | Relevance: 99%
- This article from Yahoo details a strategic collaboration between Octave Bioscience and Quest Diagnostics. The partnership aims to expand patient access to Octave's Multiple Sclerosis Disease Activity (MSDA) Test throughout the United States. This will likely improve the availability of advanced diagnostic tools for managing multiple sclerosis.

**3. Quest Diagnostics Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170500 | Neutral | Relevance: 98%
-  Quest Diagnostics Inc. (DGX) stock fell 2.86% to $183.77 on Monday, underperforming the broader market. This marked the stock's third consecutive day of losses, as the S&P 500 Index (SPX) declined 0.53% and the Dow Jones Industrial Average (DJIA) fell 0.90%.

**4. Quest Diagnostics (NYSE: DGX) to offer Octave MSDA MS blood test at 7,000 U.S. sites**
- Source: Stock Titan | 20251201T083000 | Bullish | Relevance: 98%
- Octave Bioscience has announced a strategic collaboration with Quest Diagnostics to expand access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. This partnership will allow patients to access the blood test at approximately 7,000 Quest Diagnostics patient access sites nationwide, making it easier for physicians to order and utilize for informed treatment decisions for MS patients. The collaboration also establishes a pathway for future novel tests from Octave's precision neurology portfolio.

**5. Assessing the Value of Quest Diagnostics After Expansion and Strategic Partnerships in 2025**
- Source: Simply Wall Street | 20251129T062148 | Bullish | Relevance: 98%
- This article assesses the value of Quest Diagnostics (NYSE:DGX) following recent expansion and strategic partnerships, noting its 25.7% year-to-date and 69.7% five-year stock gains. Utilizing Discounted Cash Flow and Price-to-Earnings ratio analyses, the company is found to be undervalued by 15.6% and by its "Fair Ratio" metric, respectively. The piece also introduces "Narratives" as a community-driven approach to valuation for a more dynamic and contextual investment perspective.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.7x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.7 |
| Current P/E | 18.7 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.0% to -4.5% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >3.0% for momentum thesis). Underperforming sector by 5.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.46% (CS: 5) | Weak |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | 0.05 | Bullish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $183.77
- **Stop Loss:** $175.93 (4.3% risk)
- **Target:** $191.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 95
- **Position Value:** $17,458.15
- **Portfolio %:** 17.46%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*